

Supplementary Material

Cost-per-responder analysis for tralokinumab and dupilumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis

Marni Wiseman^{1, 2}, Marco Benvenuto³, Liv Strømkjær⁴, Asger Paludan-Müller⁴, Lasse Rytting⁵, Anne Sohr Petersen⁵, Andreas Wollenberg^{6, 7, 8}

¹ Wiseman Dermatology Research inc., 6-1170 Taylor Ave, Winnipeg, Manitoba, Canada

² SKiNWISE DERMATOLOGY, 6-1170 Taylor Ave, Winnipeg, Manitoba, Canada

³ Ricercatore Universitario, Economia Aziendale, Dipartimento di Scienze dell'Economia, Università del Salento, Lecce, Italy

⁴ NHTA APS, Nelson Mandelas Allé 14, 2450-Copenhagen, Denmark

⁵ LEO pharma A/S, Industriparken 55, 2750-Ballerup, Denmark

⁶ Dept of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany

⁷ Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany

⁸ Dept. of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany

Corresponding author: Liv Strømkjær

Full postal address: NHTA ApS. Nelson Mandelas Allé 14, 1. sal. DK-2450 Copenhagen, Denmark

Email: ls@nhta.com

Table S1. Cost-per-responder for EASI-75 at 32-week

	Cost-per-responder					
	Tralokinumab					
Country, month and year of pricing, type of pricing	10% change dosing to Q4W at week 16	20% change dosing to Q4W at week 16	30% change dosing to Q4W at week 16	40% change dosing to Q4W at week 16	50% change dosing to Q4W at week 16	Dupilu- mab
Europe (€)						
France, May 2024, WPP	7,673.26	7,488.37	7,303.47	7,118.57	6,933.67	12,644.78
Germany, Juli 2024 Ex-factory prices	12,070.29	11,779.44	11,488.59	11,197.74	10,906.89	12,380.21
Italy December 2022, Ex-factory prices	13,410.01	13,086.88	12,763.75	12,440.62	12,117.48	13,656.75
UK ¹ , April 2024, Public list prices	15,003.38	14,641.85	14,280.33	13,918.80	13,557.27	18,065.16
North America (C\$)						
Canada, April 2025, Ex-factory prices	20,982.86	20,477.25	19,971.64	19,466.03	18,960.42	23,140.33

¹ £/€ exchange rate: 1.21, December 9, 2024, 10:00 UTC xe.com
Abbreviations: Q4W; Once every 4 weeks, WPP; Wholesale Pharmacy Price. €; Euro’s, C\$;
Canadian Dollar, £; British pound sterling (GDP)

Table S2. Cost-per-responder for IGA-0/1 at 32-week

	Cost-per-responder					
	Tralokinumab					
Country, month and year of pricing, type of pricing	10% change dosing to Q4W at week 16	20% change dosing to Q4W at week 16	30% change dosing to Q4W at week 16	40% change dosing to Q4W at week 16	50% change dosing to Q4W at week 16	Dupilu- mab
Europe (€)						
France, May 2024, WPP	10,994.76	10,729.82	10,464.89	10,199.95	9,935.02	23,133.84
Germany, Juli 2024 Ex-factory prices	17,295.10	16,878.35	16,461.61	16,044.86	15,628.11	22,649.80
Italy December 2022, Ex-factory prices	19,214.75	18,751.74	18,288.74	17,825.73	17,362.73	24,985.24
UK ¹ , April 2024, Public list prices	21,497.83	20,979.81	20,461.79	19,943.77	19,425.75	33,050.51
North America (C\$)						
Canada, April 2025, Ex-factory prices	30,065.63	29,341.15	28,616.68	27,892.21	27,167.74	42,335.62

¹ £/€ exchange rate: 1.21, December 9, 2024, 10:00 UTC xe.com
Abbreviations: Q4W; Once every 4 weeks, WPP; Wholesale Pharmacy Price. €; Euro's, C\$;
Canadian Dollar, £; British pound sterling (GDP)

Table S3. Results of sensitivity analysis – EASI-75

	10% of tralokinumab patients switching to Q4W dosing			40% of tralokinumab patients switching to Q4W dosing		
Country	CPR - Tralokinuma b	CPR - Dupilumab	Difference	CPR - Tralokinumab	CPR - Dupilumab	Difference
Europe (€)						
France	11,036.79	12,676.60	-4,992.59	7,157.83	12,728.54	-5,570.71
Germany	12,807.19	12,411.36	-324.17	11,259.50	12,462.22	-1,202.72
Italy	13,428.79	13,691.11	-262.32	12,509.23	13,747.21	-1,237.98
United Kingdom ¹	15,024.39	18,110.61	-3,086.23	13,995.57	18,184.82	-4,189.26
North America (C\$)						
Canada	21,085.18	23,264.97	-2,179.79	21,091.06	23,234.94	-2,143.88

¹ £/€ exchange rate: 1.21, December 9, 2024, 10:00 UTC xe.com
Abbreviations: Q4W; Once every 4 weeks, €; Euro's, C\$; Canadian Dollar, £; British pound sterling (GDP)

Table S4. Results of sensitivity analysis – IGA 0/1

	10% of tralokinumab patients switching to Q4W dosing			40% of tralokinumab patients switching to Q4W dosing		
Country	CPR - Tralokinuma b	CPR - Dupilumab	Difference	CPR - Tralokinumab	CPR - Dupilumab	Difference
Europe (€)						
France	11,067.62	23,591.81	-12,524.20	10,291.12	23,697.05	-13,405.93
Germany	17,409.72	23,098.18	-5,688.47	16,188.26	23,201.22	-7,012.96
Italy	19,342.08	25,479.86	-6,137.78	17,985.06	25,593.52	-7,608.47
United Kingdom ¹	15,024.39	18,110.61	-3,086.23	13,995.57	18,184.82	-4,189.26
North America (C\$)						
Canada	30,443.54	43,422.96	-12,979.42	30,180.57	43,013.31	-12,832.75

¹ £/€ exchange rate: 1.21, December 9, 2024, 10:00 UTC xe.com
Abbreviations: Q4W; Once every 4 weeks, €; Euro's, C\$; Canadian Dollar, £; British pound sterling (GDP)

Figure S1. Violin plots for sensitivity analysis results when 10% change to Q4W (once every 4 weeks) dosing for EASI-75




Figure S2. Violin plots for sensitivity analysis results when 10% change to Q4W (once every 4 weeks) dosing for IGA 0/1




Figure S3. Violin plots for sensitivity analysis results when 40% change to Q4W (once every 4 weeks) dosing for EASI-75




Figure S4. Violin plots for sensitivity analysis results when 40% change to Q4W (once every 4 weeks) dosing for IGA 0/1

